Published 11 May 2009, doi:10.1136/bmj.b1914
Cite this as: BMJ 2009;338:b1914

News

Merck defends Vioxx in court, as publisher apologises for fake journal

Ray Moynihan

1 Byron Bay, New South Wales

The first 150 words of the full text of this article appear below.

Merck has begun the defence of its anti-arthritis drug rofecoxib (Vioxx) in the Federal Court of Australia, amid revelations that it lobbied to quash similar legal action in Britain, and as a publisher apologised for a journal sponsored by the company.

The United States based company is fighting a class action from more than 1000 Australians, led by Graeme Peterson, who had a heart attack in 2003 after taking rofecoxib for several years.

Over the past month Mr Peterson’s lawyers have released many internal company documents showing, they claim, how Merck’s marketing tried to minimise safety concerns about the drug and to "neutralise" and "discredit" potential critics. They also say that the company created an entire medical journal that appeared to be a legitimate peer reviewed journal but that in reality was simply a "marketing publication" (BMJ 2009;338:b1714, 28 Apr, doi:10.1136/bmj.b1714).

Opening the defence case last week, . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Merck disguised "marketing publication" as medical journal to help promote Vioxx, court hears
Ray Moynihan
BMJ 2009 338: b1714. [Extract] [Full Text]

Access jobs at BMJ Careers
Whats new online at Student BMJ